<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Therapeutic apheresis complications and prevention/mitigation strategies</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Therapeutic apheresis complications and prevention/mitigation strategies</h1>
<div class="graphic"><div class="figure"><div class="ttl">Therapeutic apheresis complications and prevention/mitigation strategies</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="50%"></colgroup> <tbody> <tr> <td class="subtitle1">Complication</td> <td class="subtitle1">Prevention/mitigation strategy</td> </tr> <tr> <td>Hypocalcemia: <ul class="decimal_heading"> <li>Due to citrate, which chelates calcium</li> </ul> </td> <td> <ul> <li>Pretreatment with prophylactic calcium administration. The calcium formulation (oral, intravenous push, or continuous infusion) and dose are based on patient and procedure factors including: <ul> <li>The patient's preprocedure calcium level</li> <li>Whether the patient has known citrate sensitivity or conditions that can affect calcium metabolism</li> <li>Duration of the apheresis procedure</li> <li>Volume of citrate-containing fluids administered</li> </ul> </li> <li>Perform cardiac monitoring during continuous calcium infusion.</li> <li>Consider monitoring intraprocedural calcium levels.</li> <li>Use of plasma as a replacement fluid should only be done for specific indications.*</li> </ul> </td> </tr> <tr> <td>Other electrolyte fluctuations</td> <td> <ul> <li>Evaluate electrolytes prior to the procedure.</li> <li>Manage abnormalities as indicated.</li> </ul> </td> </tr> <tr> <td>Vascular complications: <ul class="decimal_heading"> <li>Peripheral veins</li> <li>Indwelling intravascular catheters and vascular access devices</li> </ul> </td> <td> <ul> <li>Select optimal vein for accessibility, size, and location, based on the number and length of procedures.</li> <li>For indwelling devices: <ul> <li>Follow standards of practice and institutional best practices for insertion and care.</li> <li>Confirm placement radiologically prior to apheresis procedures, in compliance with standards of practice and AABB standards.</li> <li>Evaluate coagulation parameters before removing the catheter.</li> </ul> </li> </ul> </td> </tr> <tr> <td>Transfusion reactions: <ul class="decimal_heading"> <li>Includes anaphylactoid, allergic, hypotensive, septic, or hemolytic reactions; and TRALI or TACO</li> <li>Due to plasma as the replacement fluid or RBCs during RBC exchange transfusion, or other blood products</li> </ul> </td> <td> <ul> <li>Follow PBM guidelines and institutional guidelines (if based on PBM guidelines) for blood product use.</li> <li>Avoid or minimize blood product exposure by only using blood products if indicated (especially plasma*).</li> <li>Monitor for transfusion complications; evaluate and manage per institutional policies and procedures and standards of care.</li> <li>If there is a history of anaphylaxis, check IgA and anti-IgA levels preprocedure; if results are consistent with IgA deficiency, provide blood products obtained from known IgA-deficient donors (may be available from special registries or inventories).</li> <li>For minor allergic reactions, consider premedication with an antihistamine if tolerated and not contraindicated.</li> </ul> </td> </tr> <tr> <td>Volume overload: <ul class="decimal_heading"> <li>Increased intravascular volume prior to the procedure</li> <li>Underlying heart, kidney, or liver disease</li> <li>Rapid fluid shifts</li> <li>TACO</li> </ul> </td> <td> <ul> <li>Manage overload (eg, administer diuretics) before, during, or after the procedure if indicated.</li> <li>Monitor fluid status during the procedure.</li> </ul> </td> </tr> <tr> <td>Hypotension: <ul class="decimal_heading"> <li>Underlying heart, kidney, or liver disease</li> <li>Low intravascular volume before the procedure</li> <li>Transfusion reactions</li> <li>ACE inhibitor-associated hypotension</li> <li>Membrane incompatibility with plasma membrane separation</li> <li>Other causes</li> </ul> </td> <td> <ul> <li>Clinical evaluation and treatment for the underlying cause.</li> <li>Optimize volume status prior to apheresis and monitor volume status during apheresis.</li> <li>Consider discontinuation of the ACE inhibitor (and possibly substitution of an alternate medication) 24 to 48 hours before the procedure; change to a different albumin lot if the reaction recurs.</li> <li>For plasma membrane separation, change the membrane or use a therapy other than apheresis.</li> <li>For other causes, manage as needed.</li> </ul> </td> </tr> <tr> <td>Removal/clinically relevant decrease in certain proteins or medications: <ul class="decimal_heading"> <li>Coagulation factors</li> <li>Endogenous immunoglobulins</li> <li>Therapeutic monoclonal antibodies</li> <li>Other medications</li> </ul> </td> <td> <ul> <li>Measure preprocedure PT and aPTT.</li> <li>Measure levels of immunoglobulins if hypogammaglobulinemia is a concern.</li> <li>Administer immune globulin as indicated.</li> <li>Administer clotting factors or plasma if bleeding is a significant concern; hematologist consultation is advised.</li> <li>Perform preprocedure medication review.</li> <li>Delay medications that are removed by apheresis; administer after the apheresis procedure is completed.</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table is only intended to provide general guidelines; final mitigation and treatment decisions should be based on individual patient evaluation, specialty standards of practice, institutional best practices, and current peer-reviewed literature. Refer to UpToDate topics on therapeutic apheresis for additional information about indications and complications. Refer to topics on specific transfusion reactions for evaluation and management.</div><div class="graphic_footnotes"><p>TRALI: transfusion-related acute lung injury; TACO: transfusion associated circulatory overload; RBC: red blood cell; AABB: Association for the Advancement of Blood &amp; Biotherapies; PBM: patient blood management; IgA: immunoglobin A; ACE inhibitor: angiotensin-converting enzyme inhibitor; PT: prothrombin time; aPTT: activated partial thromboplastin time; TTP: thrombotic thrombocytopenic purpura; ASFA: American Society for Apheresis.</p>
* Most indications for therapeutic apheresis do not require plasma as a replacement fluid. TTP is an exception in which plasma is an appropriate apheresis replacement fluid if recombinant ADAMTS13 is not used. Refer to the most recent ASFA guidelines for specific indications; ASFA guidelines are generally updated every three years and published in the Journal of Clinical Apheresis.</div><div id="graphicVersion">Graphic 138422 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
